๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study

โœ Scribed by R. Fenk; P. Schneider; M. Kropff; A. N. Huenerlituerkoglu; U. Steidl; C. Aul; B. Hildebrandt; R. Haas; A. Heyll; G. Kobbe; the West German Myeloma Study Group

Book ID
108673328
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
123 KB
Volume
130
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Cyclophosphamide plus dexamethasone is a
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
โœ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 153 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes highโ€dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame